Journal of Research in Pharmacy Practice

REVIEW ARTICLE
Year
: 2021  |  Volume : 10  |  Issue : 3  |  Page : 114--124

Homocysteine-lowering interventions in chronic kidney disease


Shirinsadat Badri1, Sahar Vahdat3, Shiva Seirafian3, Morteza Pourfarzam2, Tahereh Gholipur-Shahraki3, Sara Ataei4 
1 Department of Clinical Pharmacy and Pharmacy Practice; Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
2 Department of Clinical Biochemistry, Isfahan University of Medical Sciences, Isfahan, Iran
3 Department of Clinical Pharmacy and Pharmacy Practice, Isfahan University of Medical Sciences, Isfahan, Iran
4 Department of Clinical Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran

Correspondence Address:
Dr. Tahereh Gholipur-Shahraki
Department of Clinical Pharmacy and Pharmacy Practice, Isfahan University of Medical Sciences, Isfahan
Iran

The incidence of cardiovascular events and mortality is higher in patients with chronic kidney disease (CKD) compared to the general population. Homocysteine (Hcy) appears to be an independent risk factor for cardiovascular diseases in general populations and patients with CKD. Further, hyperhomocysteinemia can cause endothelial damage and increase the activity and production of coagulation factors, and its prevalence among patients with end-stage renal disease is approximately 85%–100%. Most treatments, which lower Hcy levels and have been considered in previous studies, include folic acid, B vitamins, omega-3 fatty acids, and N-acetylcysteine. However, the effect of therapies that can decrease Hcy levels and thus cardiovascular events in these patients is still unclear. The results are conflicting and require further investigation. To guide treatment decisions and improve patient outcomes, multiple databases were searched, including Web of Science, PubMed, and Medline to summarize the available evidence (i.e., clinical trial and meta-analyses) on Hcy-lowering interventions and cardiovascular events.


How to cite this article:
Badri S, Vahdat S, Seirafian S, Pourfarzam M, Gholipur-Shahraki T, Ataei S. Homocysteine-lowering interventions in chronic kidney disease.J Res Pharm Pract 2021;10:114-124


How to cite this URL:
Badri S, Vahdat S, Seirafian S, Pourfarzam M, Gholipur-Shahraki T, Ataei S. Homocysteine-lowering interventions in chronic kidney disease. J Res Pharm Pract [serial online] 2021 [cited 2022 Jan 24 ];10:114-124
Available from: https://www.jrpp.net/article.asp?issn=2319-9644;year=2021;volume=10;issue=3;spage=114;epage=124;aulast=Badri;type=0